Ann Hunter
Chief Executive Officer chez OI Pharma Partners Ltd.
Fortune : 139 268 $ au 31/03/2024
Profil
Ann Jacqueline Hunter is the founder and Chief Executive Officer of OI Pharma Partners Ltd., which was founded in 2010.
She is currently the Chairman of Stevenage Bioscience Catalyst, The Sainsbury Laboratory, Brainomix Ltd., and a Director at the Agency for Science, Technology & Research.
She is also a Director at Neurosymptomatix Ltd., BenevolentAI Bio Ltd., and a Board Member at Agency For Science Technology & Research Ventures.
Dr. Hunter previously served as the Chief Executive Officer of Biotechnology & Biological Sciences Research Council from 2013 to 2016 and as a Non-Executive Director at Proximagen Group Plc from 2010 to 2012.
She has also held positions as a Non-Executive Director at Chiltern International Ltd., Labcorp International Group Ltd., and BenevolentAI Ltd.
Additionally, she was a Senior Vice President at GSK Plc.
Dr. Hunter holds undergraduate and doctorate degrees from Royal Holloway University of London.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
BENEVOLENTAI S.A.
0,13% | 31/12/2022 | 192 465 ( 0,13% ) | 139 268 $ | 31/03/2024 |
Postes actifs de Ann Hunter
| Sociétés | Poste | Début |
|---|---|---|
| OI Pharma Partners Ltd. | Chief Executive Officer | 01/01/2010 |
| Neurosymptomatix Ltd. | Director/Board Member | - |
BenevolentAI Bio Ltd.
 BenevolentAI Bio Ltd. Packaged SoftwareTechnology Services Part of BenevolentAI SA, BenevolentAI Bio Ltd. is a clinical-stage AI-enabled drug discovery and British development company founded in 2013. The private company is based in London, UK. BenevolentAI Bio uses AI to augment scientific ingenuity in the drug discovery process, from target identification to clinical development, with the goal of improving the probability of clinical success. The company has refined and formalized its approach to sustainability under the direction of the newly established environmental, social, and governance (ESG) governance structure and teams. BenevolentAI Bio's AI-enabled Benevolent Platform™ empowers scientists to uncover new insights from data, helping to accelerate innovation and increase the probability of discovering a successful drug. | Director/Board Member | 23/03/2016 |
Brainomix Ltd.
 Brainomix Ltd. BiotechnologyHealth Technology Brainomix Ltd. develops imaging biomarkers for neurological and cerebrovascular disorders. It offers e-ASPECTS, medical imaging software that automates a scoring system on brain images from acute ischaemic stroke patients to identify and quantify signs of early stroke damage and assist the physician's decision to treat. The company founded by Michalis Papadakis, Alastair Buchan, Iris Grunwald, Constantin Thiopoulos, and Michael Printzos in 2010 and is headquartered in Oxford, the United Kingdom. | Chairman | 12/10/2020 |
Stevenage Bioscience Catalyst
 Stevenage Bioscience Catalyst BiotechnologyHealth Technology Stevenage Bioscience Catalyst offers access to equipment and facilities that would otherwise be beyond the reach of small or medium-sized companies. The company is headquartered in Stevenage, the United Kingdom. | Chairman | 01/09/2020 |
The Sainsbury Laboratory
 The Sainsbury Laboratory Medical/Nursing ServicesHealth Services The Sainsbury Laboratory is a plant and microbial research company based in Norwich, UK. The British company has confirmed funding for the development of a plant and microbial science and innovation hub. The private company has recently gained insight into pathogen suppression of plant immune receptor networks, which delivers exciting innovation for disease resistance. The company has also published research on Phytophthora sojae and Pseudomonas syringae pv. tomato DC3000 extracellular vesicles. The company will be present at the Royal Norfolk Show in 2023. The company was founded in 1987. | Chairman | - |
Agency for Science, Technology & Research
 Agency for Science, Technology & Research Miscellaneous Commercial ServicesCommercial Services Agency for Science, Technology & Research engages in fostering scientific research and development. It is the agency for fostering world-class scientific research and talent for a vibrant knowledge-based and innovation-driven Singapore. The company was founded in 1991 and is headquartered in Singapore. | Director/Board Member | 01/04/2021 |
Agency For Science Technology & Research Ventures
 Agency For Science Technology & Research Ventures Investment ManagersFinance Agency For Science Technology & Research Ventures is a Venture Capital firm, a subsidiary of Agency for Science, Technology & Research founded in 1991 with headquartered in Singapore. | Private Equity Investor | - |
Anciens postes connus de Ann Hunter
| Sociétés | Poste | Fin |
|---|---|---|
| BENEVOLENTAI | Director/Board Member | 20/06/2023 |
| ░░░░░░░ ░░░░░░░░░░░░░ ░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░░░░░░░ ░░░░░ ░░░░░░░░░░ ░░░░░░░░ ░░░░░░░░ ░░░░░░░ | ░░░░░ ░░░░░░░░░ ░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░░░░ ░░░░░ ░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | - |
Formation de Ann Hunter
| Royal Holloway University of London | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| GSK PLC | Health Technology |
| BENEVOLENTAI | Health Technology |
| Entreprise privées | 13 |
|---|---|
Proximagen Group Plc
 Proximagen Group Plc Miscellaneous Commercial ServicesCommercial Services Proximagen Group Plc engages in the business of discovery and development of therapeutic treatments. The company was founded by Jenner Peter on November 2003 and is headquartered in Cambridge, the United Kingdom. | Commercial Services |
Agency for Science, Technology & Research
Agency for Science, Technology & Research Miscellaneous Commercial ServicesCommercial Services Agency for Science, Technology & Research engages in fostering scientific research and development. It is the agency for fostering world-class scientific research and talent for a vibrant knowledge-based and innovation-driven Singapore. The company was founded in 1991 and is headquartered in Singapore. | Commercial Services |
Chiltern International Ltd.
 Chiltern International Ltd. Miscellaneous Commercial ServicesCommercial Services Chiltern International, Inc. provides clinical research services. It offers clinical development, medical and scientific affairs, data and analysis, pharmacovigilance and strategic regulatory services. The firm serves biotech, pharmaceuticals, biosimilars and biologics and medical device and diagnostics industries. The company was founded in 1982 and is headquartered in Slough, the United Kingdom. | Commercial Services |
Biotechnology & Biological Sciences Research Council
 Biotechnology & Biological Sciences Research Council Miscellaneous Commercial ServicesCommercial Services Biotechnology & Biological Sciences Research Council operates a funding agency for academic research and training. It funds bioscience, people and research infrastructure that helps to tackle major challenges such as the impact of climate change, a healthier old age, and sustainable food production, land use and energy production. The company is headquartered in Swindon, the United Kingdom. | Commercial Services |
Labcorp International Group Ltd.
 Labcorp International Group Ltd. Miscellaneous Commercial ServicesCommercial Services Chiltern International Group Ltd. operates as a holding company with interests in providing clinical development and other outsourced services to the pharmaceutical, medical device and biotechnology industries. The company was founded on May 23, 2006 and is headquartered in Edinburgh, the United Kingdom. | Commercial Services |
Stevenage Bioscience Catalyst
Stevenage Bioscience Catalyst BiotechnologyHealth Technology Stevenage Bioscience Catalyst offers access to equipment and facilities that would otherwise be beyond the reach of small or medium-sized companies. The company is headquartered in Stevenage, the United Kingdom. | Health Technology |
| OI Pharma Partners Ltd. | |
| Neurosymptomatix Ltd. | |
Agency For Science Technology & Research Ventures
Agency For Science Technology & Research Ventures Investment ManagersFinance Agency For Science Technology & Research Ventures is a Venture Capital firm, a subsidiary of Agency for Science, Technology & Research founded in 1991 with headquartered in Singapore. | Finance |
The Sainsbury Laboratory
The Sainsbury Laboratory Medical/Nursing ServicesHealth Services The Sainsbury Laboratory is a plant and microbial research company based in Norwich, UK. The British company has confirmed funding for the development of a plant and microbial science and innovation hub. The private company has recently gained insight into pathogen suppression of plant immune receptor networks, which delivers exciting innovation for disease resistance. The company has also published research on Phytophthora sojae and Pseudomonas syringae pv. tomato DC3000 extracellular vesicles. The company will be present at the Royal Norfolk Show in 2023. The company was founded in 1987. | Health Services |
Brainomix Ltd.
Brainomix Ltd. BiotechnologyHealth Technology Brainomix Ltd. develops imaging biomarkers for neurological and cerebrovascular disorders. It offers e-ASPECTS, medical imaging software that automates a scoring system on brain images from acute ischaemic stroke patients to identify and quantify signs of early stroke damage and assist the physician's decision to treat. The company founded by Michalis Papadakis, Alastair Buchan, Iris Grunwald, Constantin Thiopoulos, and Michael Printzos in 2010 and is headquartered in Oxford, the United Kingdom. | Health Technology |
BenevolentAI Ltd.
 BenevolentAI Ltd. Packaged SoftwareTechnology Services Part of BenevolentAI SA, BenevolentAI Ltd. develops artificial intelligence applications. The private company is based in London, UK. The British company was founded in 2015 by Kenneth Patrick Mulvany, Ivan Griffin, Michael Brennan. BenevolentAI was acquired by Odyssey Acquisition SA on April 22, 2022 for $1,087.33 million. | Technology Services |
BenevolentAI Bio Ltd.
BenevolentAI Bio Ltd. Packaged SoftwareTechnology Services Part of BenevolentAI SA, BenevolentAI Bio Ltd. is a clinical-stage AI-enabled drug discovery and British development company founded in 2013. The private company is based in London, UK. BenevolentAI Bio uses AI to augment scientific ingenuity in the drug discovery process, from target identification to clinical development, with the goal of improving the probability of clinical success. The company has refined and formalized its approach to sustainability under the direction of the newly established environmental, social, and governance (ESG) governance structure and teams. BenevolentAI Bio's AI-enabled Benevolent Platform™ empowers scientists to uncover new insights from data, helping to accelerate innovation and increase the probability of discovering a successful drug. | Technology Services |
